CD274 and neoplasm: For example, in our own work, we have integrated tumor immunogenic and cell proliferation signatures with PD-L1 IHC and TMB testing and have shown that tumors that are at least moderately immunogenic have significantly better survival for checkpoint inhibition compared with highly proliferative tumors with weak immunogenicity.